Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants

Overview

Journal J Mol Biol

Publisher Elsevier

Specialties Microbiology
Molecular Biology

Date 2021 May 23

PMID 34023401

Citations 132

Authors

Charlie Laffeber

Kelly de Koning

Roland Kanaar

Joyce H G Lebbink

Affiliations

Soon will be listed here.

Abstract

Rapidly spreading new variants of SARS-CoV-2 carry multiple mutations in the viral spike protein which attaches to the angiotensin converting enzyme 2 (ACE2) receptor on host cells. Among these mutations are amino acid changes N501Y (lineage B.1.1.7, first identified in the UK), and the combination N501Y, E484K, K417N (B.1.351, first identified in South Africa), all located at the interface on the receptor binding domain (RBD). We experimentally establish that RBD containing the N501Y mutation results in 7-fold stronger binding to the hACE2 receptor than wild type RBD. The E484K mutation only slightly enhances the affinity for the receptor, while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds 3-fold stronger to hACE2 than wild type RBD but 2-fold weaker than N501Y. However, the recently emerging double mutant E484K/N501Y binds even stronger than N501Y. The independent evolution of lineages containing mutations with different effects on receptor binding affinity, viral transmission and immune evasion underscores the importance of global viral genome surveillance and functional characterization.

Citing Articles

Structural and Conformational Impact of Deleterious Spike Protein Mutations in SARS-CoV-2 Omicron Lineages.

Khalid A, Ahmed K, Kanji A, Munir T, Bukhari S, Hasan Z bioRxiv. 2025; .

PMID: 40060440 PMC: 11888324. DOI: 10.1101/2025.02.25.639252.

Current Updates on Variants of SARS-CoV- 2: Systematic Review.

Erkihun M, Ayele B, Asmare Z, Endalamaw K Health Sci Rep. 2024; 7(11):e70166.

PMID: 39502131 PMC: 11534727. DOI: 10.1002/hsr2.70166.

COVID-19 mutations: An overview.

Sarkar M, Madabhavi I World J Methodol. 2024; 14(3):89761.

PMID: 39310238 PMC: 11230071. DOI: 10.5662/wjm.v14.i3.89761.

Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition.

Asor R, Olerinyova A, Burnap S, Kushwah M, Soltermann F, Rudden L Proc Natl Acad Sci U S A. 2024; 121(40):e2403260121.

PMID: 39298475 PMC: 11459207. DOI: 10.1073/pnas.2403260121.

In vitro antibody-mediated SARS-CoV-2 infection suppression through human ACE2 receptor blockade.

Redd P, Merting A, Klement J, Poschel D, Yang D, Liu K Immunol Lett. 2024; 268:106887.

PMID: 38925442 PMC: 11256821. DOI: 10.1016/j.imlet.2024.106887.

References

Yuan M, Huang D, Lee C, Wu N, Jackson A, Zhu X . Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science. 2021; 373(6556):818-823. PMC: 8284396. DOI: 10.1126/science.abh1139. View

Korber B, Fischer W, Gnanakaran S, Yoon H, Theiler J, Abfalterer W . Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020; 182(4):812-827.e19. PMC: 7332439. DOI: 10.1016/j.cell.2020.06.043. View

Greaney A, Loes A, Crawford K, Starr T, Malone K, Chu H . Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021; 29(3):463-476.e6. PMC: 7869748. DOI: 10.1016/j.chom.2021.02.003. View

Andreano E, Piccini G, Licastro D, Casalino L, Johnson N, Paciello I . SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proc Natl Acad Sci U S A. 2021; 118(36). PMC: 8433494. DOI: 10.1073/pnas.2103154118. View

Liu Z, VanBlargan L, Bloyet L, Rothlauf P, Chen R, Stumpf S . Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021; 29(3):477-488.e4. PMC: 7839837. DOI: 10.1016/j.chom.2021.01.014. View

Gobeil S, Janowska K, McDowell S, Mansouri K, Parks R, Manne K . D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. Cell Rep. 2021; 34(2):108630. PMC: 7762703. DOI: 10.1016/j.celrep.2020.108630. View

Starr T, Greaney A, Hilton S, Ellis D, Crawford K, Dingens A . Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell. 2020; 182(5):1295-1310.e20. PMC: 7418704. DOI: 10.1016/j.cell.2020.08.012. View

Liu H, Zhang Q, Wei P, Chen Z, Aviszus K, Yang J . The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. Cell Res. 2021; 31(6):720-722. PMC: 8063779. DOI: 10.1038/s41422-021-00496-8. View

Ittisoponpisan S, Islam S, Khanna T, Alhuzimi E, David A, Sternberg M . Can Predicted Protein 3D Structures Provide Reliable Insights into whether Missense Variants Are Disease Associated?. J Mol Biol. 2019; 431(11):2197-2212. PMC: 6544567. DOI: 10.1016/j.jmb.2019.04.009. View

10.

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J . Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021; 592(7854):438-443. DOI: 10.1038/s41586-021-03402-9. View

11.

Liu H, Wei P, Zhang Q, Chen Z, Aviszus K, Downing W . 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab . MAbs. 2021; 13(1):1919285. PMC: 8183533. DOI: 10.1080/19420862.2021.1919285. View

12.

Joosten R, Long F, Murshudov G, Perrakis A . The PDB_REDO server for macromolecular structure model optimization. IUCrJ. 2014; 1(Pt 4):213-20. PMC: 4107921. DOI: 10.1107/S2052252514009324. View

13.

Gu H, Chen Q, Yang G, He L, Fan H, Deng Y . Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020; 369(6511):1603-1607. PMC: 7574913. DOI: 10.1126/science.abc4730. View

14.

Faria N, Mellan T, Whittaker C, Claro I, Candido D, Mishra S . Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021; 372(6544):815-821. PMC: 8139423. DOI: 10.1126/science.abh2644. View

15.

Voloch C, da Silva Francisco Jr R, de Almeida L, Cardoso C, Brustolini O, Gerber A . Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. J Virol. 2021; 95(10). PMC: 8139668. DOI: 10.1128/JVI.00119-21. View

16.

Nonaka C, Franco M, Graf T, Barcia C, de Avila Mendonca R, de Sousa K . Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil. Emerg Infect Dis. 2021; 27(5):1522-1524. PMC: 8084516. DOI: 10.3201/eid2705.210191. View

17.

Thomson E, Rosen L, Shepherd J, Spreafico R, da Silva Filipe A, Wojcechowskyj J . Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021; 184(5):1171-1187.e20. PMC: 7843029. DOI: 10.1016/j.cell.2021.01.037. View

18.

Collier D, De Marco A, Ferreira I, Meng B, Datir R, Walls A . Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021; 593(7857):136-141. PMC: 7616976. DOI: 10.1038/s41586-021-03412-7. View

19.

Gibson D, Young L, Chuang R, Venter J, Hutchison 3rd C, Smith H . Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009; 6(5):343-5. DOI: 10.1038/nmeth.1318. View

20.

Volz E, Mishra S, Chand M, Barrett J, Johnson R, Geidelberg L . Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021; 593(7858):266-269. DOI: 10.1038/s41586-021-03470-x. View